Back to Search Start Over

Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

Authors :
Rondy, M.
Gherasim, A.
Casado, I.
Launay, O.
Rizzo, C.
Pitigoi, D.
Mickiene, A.
Marbus, S. D.
Machado, A.
Syrjanen, R. K.
Pem-Novose, I.
Horvath, J. K.
Larrauri, A.
Castilla, J.
Vanhems, P.
Alfonsi, V.
Ivanciuc, A. E.
Kuliese, M.
Van Gageldonk-Lafeber, R.
Gomez, V.
Ikonen, N.
Lovric, Z.
Ferenczi, A.
Moren, A.
Pozo, F.
Garcia, M.
Latorre, M.
Omenaca, M.
Oribe Amores, M.
Munoz, N.
Cilla, G.
Fernandino, L.
Martinez-Baz, I.
Navascues, A.
Perez-Garcia, A.
Aguinaga, A.
Ezpeleta, C.
Bella, A.
Appelgren, E. C.
Castrucci, M. R.
Puzelli, S.
Chironna, M.
Germinario, C.
Ansaldi, F.
Manini, I.
Montomoli, E.
Lupulescu, E.
Lazar, M.
Mihai, M. E.
Cherciu, C. M.
Dinu, S.
Tecu, C.
Nitescu, M.
Bacruban, R.
Azamfire, D.
Dumitrescu, A.
Ianosik, E.
Ceausu, E.
Popescu, C. P.
Florescu, S. A.
Tardei, G.
Bejan, C.
Teodor, A.
Juganariu, G.
Plesca, C.
Duca, E.
Lenzi, N.
Lesieur, Z.
Loulergue, P.
Galtier, F.
Agostini, C.
Ray, M.
Merle, C.
Foulongne, V.
Lina, B.
Laine, F.
De Guibert, S.
Lagathu, G.
Tattevin, P.
Jouneau, S.
Esvant, A.
Le Gallou, T.
Carrat, F.
Mawuvi, G.
Chau, F.
Nohynek, H.
Haveri, A.
Gefenaite, G.
Velyvyte, D.
Jancoriene, L.
Zablockiene, B.
Ambrozaitis, A.
Grimalauskaite, R.
Damuleviciene, G.
Lesauskaite, V.
Bagdonas, A.
Nunes, B.
Kislaya, I.
Rodrigues, A. P.
Gomes, V.
Corte-Real, R.
Pocas, J.
Peres, M. J.
Bernard, K.
Kurecic-Filipovic, S.
Visekruna Vucina, V.
Topic, A.
Papic, N.
Budimir, J.
Oroszi, B.
Meijer, A.
Van Der Hoek, W.
Schneeberger, P. M.
EpiConcept [Paris]
Institute of Health 'Carlos III'
CIBER de Epidemiología y Salud Pública (CIBERESP)
IDISNA, Pamplona
CIC Cochin Pasteur (CIC 1417)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)
F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC)
Istituto Superiore di Sanità (ISS)
University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD)
Lithuanian University of health Sciences
National Institute for Public Health and the Environment [Bilthoven] (RIVM)
Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA)
National Institute for Health and Welfare [Helsinki]
Croatian Institute of Public Health [Zagreb] (CIPH)
Office of the Chief Medical Officer
Hôpital Edouard Herriot [CHU - HCL]
Hospices Civils de Lyon (HCL)
Laboratoire des pathogènes émergents -- Emerging Pathogens Laboratory (LPE-Fondation Mérieux)
Centre International de Recherche en Infectiologie (CIRI)
École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Institute of Biology Bucharest of Romanian Academy
Epidemiology Department
Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Istituto Superiore di Sanità Rome, Rome, Italy
Centre International de Recherche en Infectiologie - UMR (CIRI)
Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)
EpiConcept
Unión Europea
CIC Cochin Pasteur ( CIC 1417 )
Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 )
F-CRIN, I-REIVAC
Institut National de la Santé et de la Recherche Médicale ( INSERM )
National Center for Epidemiology Surveillance and Health Promotion
Istituto Superiore di Sanita [Rome]
'Carol Davila' University of Medicine and Pharmacy
National Institute for Public Health and the Environment [Bilthoven] ( RIVM )
Instituto Nacional de Saúde Doutor Ricardo Jorge
Croatian Institute of Public Health, Zagreb
Hospices Civils de Lyon ( HCL )
Centre International de Recherche en Infectiologie ( CIRI )
Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Claude Bernard Lyon 1 ( UCBL )
Université de Lyon-Université de Lyon-École normale supérieure - Lyon ( ENS Lyon )
Istituto Superiore de Sanita
HAL-UPMC, Gestionnaire
École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Source :
Eurosurveillance, Eurosurveillance, 2017, 22 (41), ⟨10.2807/1560-7917.ES.2017.22.41.17-00645⟩, Eurosurveillance, European Centre for Disease Prevention and Control, 2017, 22 (41), ⟨10.2807/1560-7917.ES.2017.22.41.17-00645⟩, Repisalud, Instituto de Salud Carlos III (ISCIII), Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid, Eurosurveillance, European Centre for Disease Prevention and Control, 2017, 22 (41), 〈http://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.41.17-00645〉. 〈10.2807/1560-7917.ES.2017.22.41.17-00645〉
Publication Year :
2017
Publisher :
European Centre for Disease Control and Prevention (ECDC), 2017.

Abstract

Members of the I-Move+hospital working group - Portugal: B. Nunes, I. Kislaya, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Côrte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal). In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate. Funding: The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446. The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). info:eu-repo/semantics/publishedVersion

Subjects

Subjects :
Male
0301 basic medicine
Pediatrics
Epidemiology
Efetividade da Vacina Antigripal
A(H3N2)
Influenza
cases control
elderly
hospitalisation
vaccine effectiveness
Elderly
0302 clinical medicine
vaccine
Outcome Assessment, Health Care
Influenza A Virus
Hospitalisation
awareness
030212 general & internal medicine
media_common
Vaccine effectiveness
virus diseases
[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie
Middle Aged
Hospitals
3. Good health
Hospitalization
Influenza Vaccines
H3N2 Subtype
Female
Seasons
influenza
Rapid Communication
Human
Adult
medicine.medical_specialty
Adolescent
Influenza vaccine
030106 microbiology
Outcome Assessment (Health Care)
03 medical and health sciences
[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology
Virology
Influenza, Human
medicine
Aged
European Union
Humans
Influenza A Virus, H3N2 Subtype
media_common.cataloged_instance
Vacina Antigripal
European union
Cases control
Cases Control
business.industry
Public health
Cuidados de Saúde
Public Health, Environmental and Occupational Health
Case-control study
Influenza a
Confidence interval
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Emergency medicine
[ SDV.IMM.VAC ] Life Sciences [q-bio]/Immunology/Vaccinology
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
Prevention control
business

Details

ISSN :
15607917 and 1025496X
Volume :
22
Database :
OpenAIRE
Journal :
Eurosurveillance
Accession number :
edsair.doi.dedup.....1e043247343a74a48a42d3c94b20cf1f
Full Text :
https://doi.org/10.2807/1560-7917.es.2017.22.41.17-00645
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details